[go: up one dir, main page]

ES2176347T3 - Modulacion de la respuesta inmune. - Google Patents

Modulacion de la respuesta inmune.

Info

Publication number
ES2176347T3
ES2176347T3 ES95939341T ES95939341T ES2176347T3 ES 2176347 T3 ES2176347 T3 ES 2176347T3 ES 95939341 T ES95939341 T ES 95939341T ES 95939341 T ES95939341 T ES 95939341T ES 2176347 T3 ES2176347 T3 ES 2176347T3
Authority
ES
Spain
Prior art keywords
molecules
immunogen
administration
immune response
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95939341T
Other languages
English (en)
Inventor
Douglas Thomas Fearon
Paul Walter Dempsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Application granted granted Critical
Publication of ES2176347T3 publication Critical patent/ES2176347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EL ACOPLAMIENTO DE MOLECULAS C3D O DE LIGANDOS CD21 O CD19 A UN ANTIGENO ALTERA EL NIVEL DE RESPUESTA INMUNE A UN INMUNOGENO CUANDO SE ADMINISTRA A UN INDIVIDUO. EN C3D, LA MAGNITUD DEL EFECTO DEPENDE DEL NUMERO DE MOLECULAS C3D INCLUIDAS EN EL CONJUGADO. LAS MOLECULAS C3D O LOS LIGANDOS CD21 O CD19 SE ACOPLAN CONVENIENTEMENTE A UN INMUNOGENO EN POLIPEPTIDOS DE FUSION QUE PUEDEN PRODUCIRSE MEDIANTE EXPRESION DEL ACIDO NUCLEICO QUE LOS CODIFICA, POR EJEMPLO, CULTIVANDO CELULAS HUESPED QUE CONTIENEN EL ACIDO NUCLEICO. OTRA FORMA DE ASOCIAR LAS MOLECULAS ES MEDIANTE RETICULACION QUIMICA Y CO-EXPRESION EN LA SUPERFICIE DE UN PORTADOR. LA ADMINISTRACION DE LA COMPOSICION, FORMADA PREFERENTEMENTE POR MOLECULAS C3D Y UN DETERMINADO INMUNOGENO SE PUEDE UTILIZAR DE FORMA PROFILACTICA (EN VIRTUD DE LA MEMORIA INMUNOLOGICA INDUCIDA) O TERAPEUTICA. LA ADMINISTRACION PUEDE ESTAR DESTINADA A AUMENTAR EL NIVEL DE ANTICUERPOS AL INMUNOGENO. TAMBIEN SE PUEDE INDUCIR UNA RESPUESTA DE LAS CELULAS T.
ES95939341T 1994-12-06 1995-12-06 Modulacion de la respuesta inmune. Expired - Lifetime ES2176347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9424631A GB9424631D0 (en) 1994-12-06 1994-12-06 Modulating the immune response

Publications (1)

Publication Number Publication Date
ES2176347T3 true ES2176347T3 (es) 2002-12-01

Family

ID=10765518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95939341T Expired - Lifetime ES2176347T3 (es) 1994-12-06 1995-12-06 Modulacion de la respuesta inmune.

Country Status (12)

Country Link
US (2) US6238670B1 (es)
EP (1) EP0797452B1 (es)
JP (1) JPH10509723A (es)
AT (1) ATE216593T1 (es)
AU (1) AU709990B2 (es)
CA (1) CA2207000A1 (es)
DE (1) DE69526521T2 (es)
DK (1) DK0797452T3 (es)
ES (1) ES2176347T3 (es)
GB (1) GB9424631D0 (es)
PT (1) PT797452E (es)
WO (1) WO1996017625A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951976A (en) 1996-03-28 1999-09-14 Whitenead Institute For Biomedical Research Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
ATE312172T1 (de) * 1997-08-05 2005-12-15 Vlaams Interuniv Inst Biotech Immunschützendes influenzaantigen und dessen verwendung zur impfung
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
GB9727512D0 (en) 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
JP5138844B2 (ja) * 1998-06-12 2013-02-06 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
EP1001021B1 (en) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
EP1387697A4 (en) * 2001-05-17 2005-04-20 Jolla Pharma METHOD FOR TREATING ANTIBODY-MEDIATED DISEASES USING MEANS TO INHIBIT CD21
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
WO2004016283A2 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
JP2004222435A (ja) * 2003-01-16 2004-08-05 Fuji Heavy Ind Ltd 電気自動車の駆動装置
WO2013110064A1 (en) * 2012-01-19 2013-07-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
WO2013139789A1 (en) * 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
EP2674168A1 (en) * 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3
AU2013285537B2 (en) 2012-07-02 2017-10-12 Medizinische Universitat Wien Complement split product C4d for the treatment of inflammatory conditions
EP3682006A1 (en) 2017-09-11 2020-07-22 Insideoutbio, Inc. Methods and compositions to enhance the immunogenicity of tumors
US20210403519A1 (en) 2018-11-02 2021-12-30 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
AU6355090A (en) * 1989-08-23 1991-04-03 Scripps Clinic And Research Foundation Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
WO1991013974A1 (en) 1990-03-14 1991-09-19 The Biomembrane Institute Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Also Published As

Publication number Publication date
US6891027B2 (en) 2005-05-10
WO1996017625A1 (en) 1996-06-13
DE69526521T2 (de) 2002-12-05
EP0797452B1 (en) 2002-04-24
AU4120496A (en) 1996-06-26
PT797452E (pt) 2002-10-31
US20020102656A1 (en) 2002-08-01
AU709990B2 (en) 1999-09-09
JPH10509723A (ja) 1998-09-22
ATE216593T1 (de) 2002-05-15
EP0797452A1 (en) 1997-10-01
CA2207000A1 (en) 1996-06-13
GB9424631D0 (en) 1995-01-25
DK0797452T3 (da) 2002-08-19
DE69526521D1 (de) 2002-05-29
US6238670B1 (en) 2001-05-29

Similar Documents

Publication Publication Date Title
ES2176347T3 (es) Modulacion de la respuesta inmune.
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
ATE47155T1 (de) Monoklonaler antikoerper.
DK338587A (da) Modulsamling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20003716D0 (no) Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
ES2181734T3 (es) Ensayo inmunologico de ciclosporina.
IE811595L (en) Synthetic peptide antigens
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
WO1998025958A3 (en) Mammalian cell surface antigens comprising structural motifs characteristic of a member of the TNF ligand family
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DE69637523D1 (de) Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
IT8720842A0 (it) Analisi immunologiva stratificata impiegando anticorpi legati a particelle di trasporto per determinare la presenza di un antigene.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
EP0363109A3 (en) Determination of a chlamydial or gonococcal antigen using a positively-charged ionically binding support
EP0248534A3 (en) Method of detecting aids virus infection
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
DE3888437D1 (de) Immobilisierte Antikörper.
DE69133185D1 (de) Entwicklung von dns-sonden und immunologischen reagenzien von menschlichen tumor-assoziierten antigenen
EP0158291A3 (en) A method for purifying carcinoembryonic antigen and a method for producing a carcinoembryonic antigen-reactive monoclonal antibody
DE3482924D1 (de) Reagenz zur verwendung im nachweis des antikoerpers gegen menschliche t-zellen-leukemievirusantigene.
DK324287A (da) Antistof mod koensspecifikt antigen